• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺癌新辅助治疗患者表观扩散系数的价值。

Values of apparent diffusion coefficient in pancreatic cancer patients receiving neoadjuvant therapy.

机构信息

College of Electronic and Information Engineering, Tongji University, Shanghai, China.

Department of Radiology, Changhai Hospital of Shanghai, Naval Medical University, Changhai Road 168, Shanghai, 200434, China.

出版信息

BMC Cancer. 2024 Sep 18;24(1):1160. doi: 10.1186/s12885-024-12934-y.

DOI:10.1186/s12885-024-12934-y
PMID:39294623
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11412028/
Abstract

BACKGROUND

To investigate the values of apparent diffusion coefficient (ADC) for the treatment response evaluation in pancreatic cancer (PC) patients receiving neoadjuvant therapy (NAT).

METHODS

This study included 103 NAT patients with histologically proven PC. ADC maps were generated using monoexponential diffusion-weighted imaging (b values: 50, 800 s/mm). Tumors' minimum, maximum, and mean ADCs were measured and compared pre- and post-NAT. Variations in ADC values measured between pre- and post-NAT completion for NAT methods (chemotherapy, chemoradiotherapy), tumor locations (head/neck, body/tail), tumor regression grade (TRG) levels (0-2, 3), N stages (N0, N1/N2) and tumor resection margin status (R0, R1), were further analyzed.

RESULTS

The minimum, maximum, and mean ADC values all increased dramatically after NAT, rising from 23.4 to 25.4% (all p < 0.001): mean (average: 1.626 × 10 mm/s vs. 1.315 × 10 mm/s), minimum (median: 1.274 × 10 mm/s vs. 1.034 × 10 mm/s), and maximum (average: 1.981 × 10 mm/s vs. 1.580 × 10 mm/s). The ADCs between the subgroups of all the criteria under investigation did not differ significantly for the minimum, maximum, or mean values pre- or post-NAT (P = 0.08 to 1.00). In the patients with borderline resectable PC (n = 47), the rate of tumor size changes after NAT was correlated with the pre-NAT mean ADC values (Spearman's coefficient: 0.288, P = 0.049).

CONCLUSIONS

The ADC values of PC increased significantly following NAT; however, the percentage increases failed to provide any predictive value for the resection margin status or TRG levels.

摘要

背景

探讨在接受新辅助治疗(NAT)的胰腺癌(PC)患者中,表观扩散系数(ADC)值对治疗反应评估的价值。

方法

本研究纳入了 103 例经组织学证实的 PC 接受 NAT 的患者。使用单指数扩散加权成像(b 值:50、800 s/mm)生成 ADC 图。测量并比较治疗前后肿瘤的最小、最大和平均 ADC 值。进一步分析治疗方法(化疗、放化疗)、肿瘤位置(头/颈、体/尾)、肿瘤消退分级(TRG)水平(0-2、3)、N 分期(N0、N1/N2)和肿瘤切除边缘状态(R0、R1)对 ADC 值变化的影响。

结果

NAT 后,最小、最大和平均 ADC 值均显著升高,分别从 23.4%升至 25.4%(均 P<0.001):平均(平均:1.626×10 mm/s 比 1.315×10 mm/s)、最小(中位数:1.274×10 mm/s 比 1.034×10 mm/s)和最大(平均:1.981×10 mm/s 比 1.580×10 mm/s)。在所有研究标准的亚组中,治疗前后的 ADC 值在最小、最大或平均方面均无显著差异(P=0.08 至 1.00)。在边界可切除 PC 患者(n=47)中,NAT 后肿瘤大小变化率与治疗前平均 ADC 值相关(Spearman 系数:0.288,P=0.049)。

结论

PC 的 ADC 值在接受 NAT 后显著升高;然而,百分比的增加并不能为切缘状态或 TRG 水平提供任何预测价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95fc/11412028/50c02c6095e5/12885_2024_12934_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95fc/11412028/ed190ee44734/12885_2024_12934_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95fc/11412028/ab33360cc392/12885_2024_12934_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95fc/11412028/50c02c6095e5/12885_2024_12934_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95fc/11412028/ed190ee44734/12885_2024_12934_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95fc/11412028/ab33360cc392/12885_2024_12934_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95fc/11412028/50c02c6095e5/12885_2024_12934_Fig3_HTML.jpg

相似文献

1
Values of apparent diffusion coefficient in pancreatic cancer patients receiving neoadjuvant therapy.胰腺癌新辅助治疗患者表观扩散系数的价值。
BMC Cancer. 2024 Sep 18;24(1):1160. doi: 10.1186/s12885-024-12934-y.
2
Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial).扩散加权 MRI 预测新辅助治疗胰腺癌患者的组织学反应:一项前瞻性研究(DIFFERENT 试验)。
Langenbecks Arch Surg. 2020 Feb;405(1):23-33. doi: 10.1007/s00423-020-01857-4. Epub 2020 Jan 28.
3
Diffusion-weighted magnetic resonance imaging of mucin pools in locally advanced rectal mucinous adenocarcinoma predicts tumor response to neoadjuvant therapy.弥散加权磁共振成像在局部进展期直肠黏液腺癌黏液池中的应用预测新辅助治疗的肿瘤反应。
Eur J Radiol. 2020 Apr;125:108890. doi: 10.1016/j.ejrad.2020.108890. Epub 2020 Feb 12.
4
Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis.扩散加权成像在评估胰腺癌新辅助治疗反应中的应用:系统评价和荟萃分析。
Eur Radiol. 2024 May;34(5):3238-3248. doi: 10.1007/s00330-023-10381-0. Epub 2023 Nov 1.
5
Tumor size measurements of pancreatic cancer with neoadjuvant therapy based on RECIST guidelines: is MRI as effective as CT?基于 RECIST 指南的新辅助治疗后胰腺癌肿瘤大小测量:MRI 与 CT 一样有效吗?
Cancer Imaging. 2023 Jan 18;23(1):8. doi: 10.1186/s40644-023-00528-z.
6
Value of apparent diffusion coefficient prior to neoadjuvant therapy is a predictor of histologic response in patients with borderline resectable pancreatic carcinoma.新辅助治疗前的表观扩散系数值是临界可切除胰腺癌患者组织学反应的预测指标。
J Hepatobiliary Pancreat Sci. 2017 Mar;24(3):161-168. doi: 10.1002/jhbp.430.
7
Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).评价胰腺癌放化疗后使用 FDG-PET/CT 和弥散加权 MRI 的疗效:一项非随机、单中心 II 期临床试验-PaCa-DD-041(Eudra-CT 2009-011968-11)。
Strahlenther Onkol. 2021 Jan;197(1):19-26. doi: 10.1007/s00066-020-01654-4. Epub 2020 Jul 7.
8
Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology.评估胃食管交界癌新辅助治疗反应的表观扩散系数改变:与组织学肿瘤退缩分级的比较。
Eur Radiol. 2013 Aug;23(8):2165-74. doi: 10.1007/s00330-013-2807-0. Epub 2013 Apr 16.
9
Diffusion-weighted magnetic resonance imaging in monitoring rectal cancer response to neoadjuvant chemoradiotherapy.弥散加权磁共振成像在监测直肠癌新辅助放化疗反应中的应用。
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):594-9. doi: 10.1016/j.ijrobp.2011.07.017. Epub 2011 Nov 16.
10
Value of diffusion-weighted MRI and apparent diffusion coefficient measurements for predicting the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy.弥散加权 MRI 及其表观弥散系数测量在预测局部进展期直肠癌新辅助放化疗疗效中的价值。
Abdom Radiol (NY). 2016 Oct;41(10):1906-17. doi: 10.1007/s00261-016-0805-9.

本文引用的文献

1
Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis.扩散加权成像在评估胰腺癌新辅助治疗反应中的应用:系统评价和荟萃分析。
Eur Radiol. 2024 May;34(5):3238-3248. doi: 10.1007/s00330-023-10381-0. Epub 2023 Nov 1.
2
Apparent diffusion coefficient correlates with different histopathological features in several intrahepatic tumors.表观扩散系数与多种肝内肿瘤的不同组织病理学特征相关。
Eur Radiol. 2023 Sep;33(9):5955-5964. doi: 10.1007/s00330-023-09788-6. Epub 2023 Jun 22.
3
Tumor size measurements of pancreatic cancer with neoadjuvant therapy based on RECIST guidelines: is MRI as effective as CT?
基于 RECIST 指南的新辅助治疗后胰腺癌肿瘤大小测量:MRI 与 CT 一样有效吗?
Cancer Imaging. 2023 Jan 18;23(1):8. doi: 10.1186/s40644-023-00528-z.
4
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
5
The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer.磁共振成像胰腺检查方案在评估可切除边缘胰腺癌患者新辅助治疗反应中的作用
Front Oncol. 2022 Jan 13;11:796317. doi: 10.3389/fonc.2021.796317. eCollection 2021.
6
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.可切除和边缘可切除胰腺癌的新辅助放化疗与 upfront 手术比较:荷兰随机 PREOPANC 试验的长期结果。
J Clin Oncol. 2022 Apr 10;40(11):1220-1230. doi: 10.1200/JCO.21.02233. Epub 2022 Jan 27.
7
Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy: Expert Panel Narrative Review.新辅助治疗后胰腺癌可切除性的影像学评估:专家小组叙事性综述。
AJR Am J Roentgenol. 2022 Apr;218(4):570-581. doi: 10.2214/AJR.21.26931. Epub 2021 Dec 1.
8
Neoadjuvant therapy for pancreatic cancer.胰腺癌的新辅助治疗。
Updates Surg. 2022 Feb;74(1):35-42. doi: 10.1007/s13304-021-01186-1. Epub 2021 Oct 9.
9
Pancreatic Cancer: A Review.胰腺癌:综述。
JAMA. 2021 Sep 7;326(9):851-862. doi: 10.1001/jama.2021.13027.
10
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.胰腺导管腺癌临床实践指南(第 2.2021 版),NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2021 Apr 1;19(4):439-457. doi: 10.6004/jnccn.2021.0017.